Skip to main content

Table 2 Response of angiomyolipoma volume to everolimus therapy

From: Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial

 

3 months

6 months

12 months

18 months

24 months

Patients (n)

18

17

15

15

14

No. of response (n,%)

9 (52.94%)

10 (58.82%)

10 (66.67%)

5(33.33%)

1(7.14%)

a% of baseline value (Mean ± SD,%)

47.73 ± 19.81

44.27 ± 23.69

41.14 ± 26.54

60.67 ± 23.28

77.62 ± 16.66

P value for change from baseline value

0.002

0.002

<0.001

0.006

0.014

  1. athe average percentage change of baseline in the total volume of all target AML lesions